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Given the difficulty of applying gene knockout technology to
species other than mice, we decided to explore the utility of RNA
interference (RNAi) in silencing the expression of genes in live-
stock. Short hairpin RNAs (shRNAs) were designed and screened for
their ability to suppress the expression of caprine and bovine prion
protein (PrP). Lentiviral vectors were used to deliver a transgene
expressing GFP and an shRNA targeting PrP into goat fibroblasts.
These cells were then used for nuclear transplantation to produce
a cloned goat fetus, which was surgically recovered at 81 days of
gestation and compared with an age-matched control derived by
natural mating. All tissues examined in the cloned fetus expressed
GFP, and PCR analysis confirmed the presence of the transgene
encoding the PrP shRNA. Most relevant, Western blot analysis
performed on brain tissues comparing the transgenic fetus with
control demonstrated a significant (>90%) decrease in PrP expres-
sion levels. To confirm that similar methodologies could be applied
to the bovine, recombinant virus was injected into the perivitelline
space of bovine ova. After in vitro fertilization and culture, 76% of
the blastocysts exhibited GFP expression, indicative that they
expressed shRNAs targeting PrP. Our results provide strong evi-
dence that the approach described here will be useful in producing
transgenic livestock conferring potential disease resistance and
provide an effective strategy for suppressing gene expression in a
variety of large-animal models.
nuclear transfer  short hairpin RNA  transgenic  bovine  caprine
Genetic engineering of animals and plants has played apivotal role in research and has been directly responsible for
many significant advances in agriculture and medicine. In an
effort to determine the biological function of mammalian genes,
embryonic stem (ES) cells can be genetically modified via
homologous recombination to ‘‘knockout’’ single genes or spe-
cific chromosomal loci, and these modified cells can be used in
the production of germ-line chimeras, which can be crossed to
create null mutants (1–4). To date, the overwhelming majority
of research involving the creation of genetically modified mam-
mals has involved work with mice. Attempts to produce knock-
out animals in other mammalian species have been limited in
large part because of an inability to derive and stably culture ES
cells. Some success has been obtained by producing transgenic
fetal fibroblasts via homologous recombination and then by
using these cells for cloning via somatic cell nuclear transfer;
however, this approach has proven to be extremely inefficient,
time consuming, and costly (5–7).
RNA interference (RNAi) is a conserved biological response
to double-stranded RNA, which mediates resistance to both
endogenous parasitic and exogenous pathogenic nucleic acids, as
well as regulates the expression of protein-coding genes (8).
Recent advances involving the use of RNAi-based technologies
promise alternative approaches for the stable silencing of genes
in a variety of different animal species including mammals.
Expression constructs producing 19–29 nucleotide-inverted re-
peats that form short double-stranded RNA hairpins or short
hairpin RNAs (shRNAs) have been demonstrated to be effective
in eliciting gene silencing (9–12). This method of producing
interfering RNAs enables induction of silencing by ‘‘classical’’
DNA expression vectors and has thus become adaptable to cell
culture and the production of transgenic animals, as well as
introduction into adult mammals by using established gene
therapy vehicles (11). Several examples of this approach have
already been reported, including recent data from our laboratory
(13), demonstrating that gene constructs expressing shRNAs
targeting specific genes can be stably incorporated into the
genome of mouse ES cells and used to create transgenic mice
exhibiting a phenotype analogous to that of the knockout animal.
Importantly, this RNAi-based suppression was passed through
the germ line as a dominant trait.
In more recent work, several studies involving mice have now
demonstrated that lentiviral vectors can be used to deliver
expression constructs encoding shRNAs into early stage em-
bryos to produce transgenic mice in which individual genes have
been targeted for silencing (14–16). Because these new meth-
odologies neither rely on homologous recombination nor are
dependent on deriving ES cells, it should be feasible to adapt this
technology to the production of transgenic animals in species
other than mice, including livestock.
With the recent concerns over prion-mediated diseases (trans-
missible spongiform encephalopathies) in livestock and their
potential transmission to humans, we decided to test an RNAi-
based technique for silencing the expression of the prion protein
(PrP) in goats and cattle. Studies have shown that reduction of
PrP expression is, in itself, sufficient to prevent infection on
exposure to the pathogenic conformer of PrP. In one genetic
background in mouse, loss of PrP expression gave completely
normal mice with no obvious phenotype (17). In another back-
ground, PrP loss was associated with disruption of sleep cycles,
but it is unclear the degree to which such a phenotype would
manifest itself in other out-bred strains of mice, let alone in other
species (18). Therefore, suppression of PrP by genetic engineer-
ing presents a reasonable approach for producing disease-
resistant livestock and, as such, preventing transmission of prion
diseases from animals to humans. In this article, we describe a
strategy for using RNAi-based techniques to create a cloned
transgenic goat fetus with dramatically reduced expression of
PrP and present evidence that these techniques will also be
adaptable to cattle. The approaches presented herein are also
suitable for the creation of other types of genetically engineered
animals that resist viral diseases or those that have improved
agricultural traits.
Results
shRNA Design and Screening. Although the majority of recent
interest in prion disease has centered on studies in cattle, the
lower biosecurity requirements for studies of scrapie prompted
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us to first test the possibility of using RNAi to suppress PrP
expression in another commercially important livestock animal,
the goat. To identify effective targeting sequences for caprine
and bovine PrP, the coding sequence was processed through a
computer algorithm that predicted a total of 24 shRNAs de-
signed against the PrP mRNA (see Materials and Methods).
Individual shRNAs were inserted into a lentiviral expression
vector in which the interfering RNAs were driven by the mouse
H1 RNase P promoter followed by ubiquitin C promoter-driven
GFP (Fig. 1A). Such a strategy has been used to create transgenic
mouse lines in which RNAi was used to stably suppress target
gene expression (10, 13).
To facilitate screening of a relatively large number of candi-
date shRNAs for PrP suppression, the coding sequence for the
caprine PrP was cloned downstream of the luciferase coding
region in pGL3. The resulting expression vector would produce
an mRNA containing the coding sequence for Firefly luciferase
followed by a nontranslated sequence of the PrP mRNA. Each
individual shRNA expression vector was transfected in combi-
nation with the Firefly luciferase-PrP expression plasmid and a
nontargeted reporter plasmid, encoding Renilla luciferase, as
a means of normalization. As a control, an shRNA targeting a
nonrelevant sequence was transfected along with the reporter
plasmids. For our initial screens, we compared the performance
of these plasmids in human embryonic kidney (HEK)-293T cells
using transient transfection. This screen was designed to rapidly
select those shRNAs that are efficiently processed by the RNAi
machinery and loaded into the RNAi-induced silencing complex
(8). In accord with previous reports, such constructs allowed us
to indirectly determine the relative capacity of a given shRNA to
suppress PrP by monitoring luciferase activity (19). From these
screens, three candidate shRNAs [F3 with 65.9% suppression
compared with the control (0.8%), F6 (56.3  0.7%), and F12
(86.5 0.7%)] were selected on the basis of their range of ability
to suppress the luciferase reporter and used in subsequent
studies (Fig. 1B).
Creation of Transgenic Cells for Somatic Cell Nuclear Transfer. In our
initial in vivo trials, a characterized adult goat fibroblast cell line
previously used in nuclear transfer (NT) experiments was in-
fected with recombinant lentivirus carrying the construct en-
coding GFP and the PrP shRNA. Whereas a fetal fibroblast cell
line may have been more optimal for cell culture, the lentiviral
approach precluded any long-term culture needs. Further, the
advantage of using a characterized cell line with proven ability
to produce live offspring prompted us to proceed using the adult
cell line. After infection, 30% of the cells contained the stably
integrated transgene as evidenced by GFP expression (Fig. 2 A
and B). These cells were selected and used for somatic cell
nuclear transfer to produce cloned transgenic goat embryos,
which were subsequently cultured in vitro to various stages of
preimplantation development. In many cases, GFP expression
could be visualized immediately after the nuclear transfer pro-
cedure but gradually disappeared through early embryonic
divisions only to reappear at the eight-cell stage in concurrence
with embryonic genome activation. Exemplary GFP-positive
hatching blastocyst can be seen in Fig. 2 C and D. Because one
of our goals was to determine the developmental competence of
the cloned transgenic embryos, a subset was placed in culture
overnight and transferred into synchronized recipient females
the following day. Each doe received 12–17 one-cell stage
embryos via surgical oviductal transfer. Overall, we transferred
a total of 158 presumptive cloned embryos into eight recipients
and obtained one pregnancy. The normal pregnancy rate for in
Fig. 1. Design and screening of the lentiviral shRNA expression vector. (A) Graphic representation of the lentiviral shRNA expression system used. This vector
is a modification of the plasmid described by Loiset al. (23) with insertion of the mouse H1 RNase P promoter driving expression of an shRNA. The sequence shown
here targets the caprine PrP mRNA (accession no. AY723292). (B) Percent suppression of the luciferase-PrP reporter by shRNAs targeting the PrP mRNA sequence.
All data are presented as the percent reduction in luciferase activity compared with the control nonrelevant shRNA. Experiments are an average of three
independent experiments, and actual percentages and standard deviations for the shRNAs are as follows: E2, 63.7 0.7%; E6, 58.5 0.8%; E7, 2.1 1.2%; E8,
8.2  0.7%; E9, 6.6  1.1%; F2, 48.7  0.8%; F3, 65.9  0.8%; F6, 56.3  0.7%; F9, 80.3  0.7%; and F12, 86.5  0.7%.
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vivo embryo transfer is60%, whereas NT rates are much lower,
1% survival. Thus, the pregnancy rates reported in this study
are in line with studies of goat NT (20) and with the results
previously recorded using this cell line (unpublished data).
Evaluation of PrP Knockdown in a Cloned Transgenic Fetus. To
examine the capacity of the shRNA to silence gene expression in
a disease-relevant manner in vivo, knockdown of the PrP had to
be evaluated in the brain. Given the need to collect brain tissue
and the fact that we only had one viable pregnancy, a decision
was made to remove the fetus to determine whether it was
transgenic and to compare PrP expression with a normal age-
matched control derived by natural mating. The fetus was
surgically recovered at 81 days of gestation, and tissues were
harvested for analysis. A control goat fetus of similar gestational
age was also harvested for comparison. All tissues derived from
the cloned fetus displayed strong GFP fluorescence consistent
with the presence of the transgene (Fig. 3). To confirm that the
shRNA expression cassette was present in the genome, DNAwas
isolated from brain tissue and used as template in PCR ampli-
fying the region between the H1 and ubiquitin promoters. As can
be seen in Fig. 4A, the transgenic goat genome contains the
shRNA expression cassette. We next assessed the ability of the
shRNA to suppress PrP expression. Protein extracts were taken
from transgenic and WT brain tissue and analyzed by Western
blot analysis. Blots were probed by using an antibody recognizing
goat PrP, which was a generous gift from Katherine O’Rourke
(U.S. Department of Agricultural–Agricultural Research Ser-
vice, Burns, OR) (21). As indicated in Fig. 4B, PrP expression
was reduced by 90% in the transgenic fetus when compared
with the control.
Because the lentivirus used to produce the nuclear donors is
replication-deficient, it is unlikely that the transgene will be
passed from the transgenic fetus to the mother; however, this
possibility has not been rigorously examined. Large-animal
models offer a unique opportunity in this regard because of their
placental physiology. Ungulates such as the bovine and caprine
concentrate their fetal placental villi together into discrete foci
termed cotyledons. Fetal cotyledons interact with maternal
regions called caruncles and together form the functional units
of the placentome, where maternal-fetal nutrient exchange takes
place. To determine whether the lentiviral transgene remained
restricted to the transgenic fetal cells, cross-sectional tissue
samples of the placentome were taken and stained for GFP
expression. As can be seen in Fig. 4 C and D, GFP expression is
restricted to the external fetal component, whereas the inner
maternal tissue remains GFP-negative.
Creation of Transgenic Embryos by Direct Injection of Recombinant
Virus Followed by in Vitro Fertilization and Embryo Culture.Given the
effectiveness of our viral vector for delivery of transgenes into
fibroblast cells growing in culture (30%) and because the
process of animal cloning is so inefficient, we decided to test the
effectiveness of our vector for delivery of the transgenes directly
into early-stage bovine embryos. This strategy, based on work by
Hofmann et al. (22) and others (23), relies on the delivery of
infectious viral particles into the perivitelline space of single-cell
ova and subsequent infection as the embryo develops. Due to the
unusually high degree of sequence conservation between caprine
and bovine PrP (96%), micromanipulation was used to inject 139
in vitromatured bovine ova with the same recombinant lentivirus
Fig. 2. GFP expression in transgenic goat fibroblasts and cloned goat
embryos. (A) Fibroblasts are shown during preparation for somatic cell nuclear
transfer. (B) Expression of the shRNA-GFP transgene in primary goat fibro-
blasts after integration of the lentiviral vector. (C) Bright-field image of the
hatching goat blastocyst shown in D. (D) Ubiquitin C promoter-driven GFP
expression in a hatching blastocyst produced via nuclear transfer by using
transgenic goat fibroblasts. Goat embryos were produced by somatic cell
nuclear transfer by using GFP-positive transgenic goat cells seen in A and B as
nuclear donors. Note the lack of fluorescence in the nondeveloping embryos.
Fig. 3. Expression of green fluorescent protein in whole-mounted tissues
from a cloned transgenic fetus (C–H). Images are transmitted (A, C, E, and G)
and fluorescent (B–D, F, and H) light micrographs of fresh tissue samples. (A
and B) Nontransgenic uterine myometrium from a recipient doe carrying a
transgenic fetus. (C andD) Fetal intestinal mesentery. (E and F) Fetal intestinal
lumen. (G and H) Fetal liver.














described above. After injection into the perivitelline space, the
ova were fertilized and cultured in vitro. Of these ova, 42 (30%)
developed to the blastocyst stage and 32 (76%) were GFP-
positive (Fig. 5).
Expression of GFP was first observed at the morula stage of
development but became much more apparent during blasto-
cyst formation. All embryos expressing GFP exhibited uniform
fluorescence throughout the inner cell mass and trophecto-
derm, without any obvious signs of mosaic expression. These
observations indicate that the virally delivered transgene
incorporated into the zygotic genome during early develop-
ment and that expression initiated at the maternal zygotic
transition as expected. Given the nature of our gene construct,
expression of GFP is indicative that the shRNA targeting PrP
was also expressed. These results strongly suggest that the
methods used here are effective in the production of trans-
genic goats and cattle containing an expression cassette elic-
iting RNAi-based silencing.
Discussion
The ability to genetically engineer animals has become a stan-
dard laboratory tool for physiological, genetic, and biomedical
research. However, mice represent the vast majority of trans-
genic animals produced to date. Additional animal models are
also of critical importance for medical research because mice are
not completely representative of human genetics and physiology.
For example, the limited life span and small size of the mouse
restricts its usefulness in studies requiring long-term evaluation
of test subjects (24, 25). Thus, development of treatments and
cures for human diseases are sometimes better derived from
comparative studies involving animal models other than mice. In
this article, we provide conclusive evidence that in a large-animal
system, lentiviral delivery of shRNAs targeting specific gene(s)
is indeed effective at reducing expression of the protein in vivo.
Furthermore, these results demonstrate that lentiviral delivery
of shRNA constructs has the capacity to stably knockdown genes
of interest, thus providing an efficient route to functional
genomic research in a large-animal model.
We acknowledge that the present study yielded only a single
transgenic fetus; however, given the inefficiencies of the nuclear
transfer procedure, this result is not unusual (26). Despite this
inefficiency, the length of the study was significantly less com-
pared with the time required by techniques using traditional
homologous recombination. Experiments presented here as well
as results by Hofmann et al. (22), obtained through direct
injection of recombinant virus into the perivitelline space of
bovine ova, clearly demonstrate the capacity to make viable
transgenic bovine embryos. The use of direct viral injection to
create transgenic zygotes instead of genetically modifying a cell
line and producing reconstructed (cloned) embryos dramatically
improves the efficiency and applicability of this technology. This
technique, coupled with the ever improving shRNA expression
cassettes, now enables a more functional approach to be taken
when studying gene function in animal species in which stem cell
technology is lacking but assisted reproductive technologies
currently exist.
RNAi holds the promise of enabling production of plants and
animals that are genetically altered to produce favorable char-
acteristics. Recent years have seen a greatly increased awareness
of threats posed to human health by diseases borne in livestock
populations. Viral pathogens, such as the avian influenza strain
H5N1, can be transmitted from domestic fowl to humans with
often lethal results (27). Similarly, the detection of prion-
mediated diseases in cattle have elicited the imposition of trade
Fig. 4. Characterization of PrP suppression in the transgenic goat. (A) PCR
amplification of the shRNA expression cassette from plasmid DNA (control), as
well as genomic DNA isolated from WT and transgenic fetal tissue. (B) Western
blot analysis of 100 and 75g of protein extract taken from WT and transgenic
fetal brain. A residual amount of PrP can be detected in the transgenic lane;
however, it is substantially reduced when compared with WT. The blot dis-
played was one of two independent replicates. (C) Immunostaining of pla-
centome cross-sections with an anti-GFP antibody. GFP-positive transgenic
cells can be seen surrounding GFP-negative maternal tissue, indicating that
expression of the lentivirally delivered GFP is restricted to fetal cells. (D)
Negative control placentome.
Fig. 5. Transgenic blastocysts produced by in vitro fertilization and embryo
culture. (A) Bright-field image of control blastocyst (noninjected ova). (B) The
same embryo as in A viewed using fluorescence microscopy. (C) Bright-field
image of a bovine blastocyst that was produced by injection of an in vitro
matured bovine ovum with a recombinant lentiviral vector encoding GFP and
an shRNA targeting PrP, followed by in vitro fertilization and embryo culture.
(D) The same embryo as in C viewed by using fluorescence microscopy. The
expression of GFP in the embryo depicted in D demonstrates that this embryo
has incorporated the transgene encoding GFP and a shRNA targeting PrP into
its genome.
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restrictions and necessitated the destruction of large numbers of
animals, with substantial economic impact. Although careful
monitoring of animal health and appropriate safety precautions
are a current approach to containing such diseases, there is
theoretical potential for creating genetically engineered strains
of animals with a natural resistance to numerous diseases.
However, genetic methods for altering livestock have thus far
been lacking.
Previous reports demonstrated that transfection of small
interfering RNAs was able to reduce the level of both the
endogenous and infectious PrPs in cell culture, but stable
suppression of PrP in a cell line by using these small interfering
RNA sequences was not demonstrated (28, 29). In this article, we
report the use of shRNAs to generate both a stable cell line and
a cloned transgenic goat fetus with drastically reduced expres-
sion of PrP, the causative agent of a neurodegenerative disease
that might be transmitted to humans. Additionally, recent work
has demonstrated RNAi to be effective in eliciting stable sup-
pression of the foot-and-mouth disease virus as well as porcine
endogenous retroviruses, both of significant concern to agricul-
ture and studies of xenotransplantation (30–32). Whereas these
methods demonstrate stable suppression in cell culture, the
successful use of this technology in creating genetically modified
livestock is not implicit. It is very likely that the methods
described herein can be adapted to the suppression of viral
sequences such as influenza, porcine endogenous retroviruses,
and foot-and-mouth disease, as well as targeting genes that result
in improved characteristics for the production of fiber, meat, or
milk products.
Materials and Methods
Production and Screening of shRNAs. The coding sequences of the
bovine and caprine mRNAs were processed through a com-
puter algorithm that predicted a total of 24 shRNAs designed
against the PrP sequence. Given the unusually high degree of
sequence conservation between the bovine and caprine PrP
mRNA (96%), several of the shRNAs designed perfectly
matched the mRNA from both species. Individual shRNAs
were ordered as antisense oligonucleotides (Sigma Genosys)
and used in PCR with a sense primer homologous to the mouse
H1 RNase P promoter to produce a PCR product containing
the H1 promoter directly upstream of the shRNA. Reaction
products were gel-purified and directionally cloned into the
pENTR-D entry vector (Invitrogen) by using the recom-
mended protocol. The shRNA sequences were verified in the
Gene Technologies Laboratory at Texas A & M University.
Subsequently, shRNA were inserted into a modified lentiviral
expression vector (23) containing the Gateway acceptor cas-
sette by using the Clonase reaction (Invitrogen) according to
manufacturer’s recommendations.
Screening of Candidate shRNAs for PrPs Suppression. Individual
shRNAs were screened indirectly by monitoring the ability of
each construct to silence a luciferase reporter gene containing
either the bovine or caprine PrP mRNA. This system evaluates
each shRNA’s capacity to silence a Firefly luciferase-PrP tran-
script by transiently transfecting each shRNA together with the
reporter gene andmeasuring luciferase activity by using methods
described by Yu et al. (19). Briefly, the coding sequence for the
caprine PrP mRNA (accession no. AY723292) was amplified
from goat testis by using RT-PCR (Invitrogen) and cloned into
the XbaI site downstream of the Firefly luciferase-coding region
in pGL3 (Clontech). Individual shRNA expression vectors were
transfected into National Institutes of Health human embryonic
kidney 293 cells (American Type Culture Collection) by using
calcium phosphate along with the Firefly-PrP expression plas-
mid and a nontargeted reporter plasmid, encoding Renilla
luciferase, as a means of normalization. Luciferase activity was
measured by using the Stop and Glow kit (Promega) on a
luminomitor according to the standard protocol. As a control, an
shRNA targeting a nonrelevant sequence was transfected along
with the reporter plasmids. Human embryonic kidney 293 cells
were used initially for the rapid screening because of their easy
transfection and consistency in cell culture. A total of 24 shRNAs
were screened in six pools containing four shRNAs each. These
pools were selected for further analysis on the basis of their
ability to consistently suppress the described luciferase reporter
in three replicate assays. Two pools demonstrating strong sup-
pression were expanded into their individual shRNAs and
screened by using the same assay.
Production and Concentration of Viral Vectors. Lentivirus was pre-
pared and concentrated by using methods described by Lois et al.
(23). Briefly, viral vectors were transfected into National Insti-
tutes of Health human embryonic kidney 293 cells by using
methods described above along with plasmids encoding the delta
packaging signal and a vesicular stomatitis virus glycoprotein
pseudotype. Medium was changed 24 h after transfection, and
cells were cultured for an additional 48 h, after which medium
was collected and recombinant virus was concentrated by using
a standard polyethylene glycol precipitation.
Viral Infection of Fibroblasts and Nuclear Transfer. Given the pre-
vious success with producing transgenic livestock by genetically
modifying fibroblasts and then using these for animal cloning, we
first decided to infect goat fibroblasts by using the lentiviral
shRNA construct followed by selection of transgenic cells for
nuclear transfer to produce cloned embryos. Caprine fibroblasts
were obtained via skin biopsy from an adult male and cultured
in DMEMF-12 with 10% FBS0.5 mgml gentamycin in a
humidified atmosphere of 5% CO2air. Cells at passage two
were transferred to six-well plates (Corning). When cells
achieved 50–60% confluency, fibroblast cells were infected by
delivery of concentrated virus directly into the culture medium
along with a 1  polybrene solution. Cells were spun at 1,000 
g for 1 h and cultured in viral medium overnight. The next day,
medium was changed, and cells were incubated for 3 days before
assessing the expression of GFP. Once GFP expression was
established (30% of exposed cells), cells were subpassed via
standard protocol and used for nuclear transfer before passage
five.
Nuclear transfer was performed as described in refs. 26 and 33.
Briefly, goat oocytes were obtained from ovaries of slaughtered
does and cultured in vitro to undergomeiotic maturation.Mature
ova were enucleated, and a GFP-positive donor cell was placed
in the perivitelline space. Donor cells were fused to the enucle-
ated ova by using two dc electrical pulses (2.0 kVcm). Recom-
bined cells were cultured in cycloheximide for 5 h, washed, and
placed in G1.3 medium (Vitrolife, Englewood, CO) in a humid-
ified atmosphere of 5% CO25% O290% N2. Cloned embryos
were either transferred to the oviduct of synchronized recipient
does on day 1 of culture or maintained in G1.3 for 3 days before
transfer to G2.3 (Vitrolife), cultured to the blastocyst stage, and
evaluated for GFP expression.
Lentiviral-Mediated Delivery of Transgenes into Bovine Zygotes.Our
second approach to deliver the shRNA constructs into embryos
was based on a report by Hofmann et al. (22). Here, injection of
recombinant lentivirus into bovine ova followed by in vitro
fertilization and embryo culture resulted in a high proportion of
transgenic embryos. Bovine ova were obtained from a local
abattoir and matured in vitro. Micromanipulation was used to
inject concentrated virus into the perivitelline space of mature
ova. After injection, the ova were fertilized in vitro by using
standard procedures and then cultured in vitro by using G1G2
embryo culture medium (20, 21) at 38.5°C in an atmosphere of














5% CO25% O290% N2. After 7 days, the embryos were
removed from the culture. The percentage of embryos devel-
oping to the blastocyst stage were recorded, and the embryos
were visualized under a fluorescent microscope to determine
whether they were transgenic as indicated by the expression of
GFP.
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